ConductScience.org, home

Paper41345602

Modelling the epidemiological impact and cost-effectiveness of possible changes to the meningococcal vaccination schedule for adolescents and young adults in the United States.

Shin T and 7 others. BMC Public Health, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Modelling the epidemiological impact and cost-effectiveness of possible changes to the meningococcal vaccination schedule for adolescents and young adults in the United States. Papers, record 41345602. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345602

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Modelling the epidemiological impact and cost-effectiveness of possible changes to the meningococcal vaccination schedule for adolescents and young adults in the United States.
PubMed
Journal
BMC Public Health
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-06-26
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shin TThomas
2Cristeau OOlivier
3Upegui AAngie
4Neary MPMaureen P
5Robertson CACorwin A
6Galarza KKatherine
7Clay EEmilie
8Wu JJianhong

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Meningococcal VaccinesMajor topic
Immunization ScheduleMajor topic
Meningococcal InfectionsMajor topic
Humans
Cost-Benefit Analysis
United States
Adolescent
Cost-Effectiveness Analysis
Young Adult
Quality-Adjusted Life Years
Child
Adult
Male
Incidence
Female

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135840033Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.Clin Microbiol Infect2022https://conductscience.org/library/papers/35840033PubMed
232228726Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors.Epidemiol Infect2020https://conductscience.org/library/papers/32228726PubMed
339173168National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2023.MMWR Morb Mortal Wkly Rep2024https://conductscience.org/library/papers/39173168PubMed
428472165Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.PLoS One2017https://conductscience.org/library/papers/28472165PubMed
525505298Meningococcal carriage among Georgia and Maryland high school students.J Infect Dis2015https://conductscience.org/library/papers/25505298PubMed
627623463Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.JAMA2016https://conductscience.org/library/papers/27623463PubMed
733631080Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.Hum Vaccin Immunother2021https://conductscience.org/library/papers/33631080PubMed
840394570Understanding the value of meningococcal vaccination for adolescents and young adults in the United States: insights from a steady-state modelling approach.BMC Public Health2025https://conductscience.org/library/papers/40394570PubMed
938048433United States Life Tables, 2021.Natl Vital Stat Rep2023https://conductscience.org/library/papers/38048433PubMed
1028027288Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.Pediatr Infect Dis J2017https://conductscience.org/library/papers/28027288PubMed
1112586669Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.BMJ2003https://conductscience.org/library/papers/12586669PubMed
1223741448Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.PLoS One2013https://conductscience.org/library/papers/23741448PubMed
1335641955Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review.BMC Public Health2022https://conductscience.org/library/papers/35641955PubMed
1434791633Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM).Infect Dis Ther2022https://conductscience.org/library/papers/34791633PubMed
1517560695Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.Vaccine2007https://conductscience.org/library/papers/17560695PubMed
1616110936Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis.Qual Life Res2005https://conductscience.org/library/papers/16110936PubMed
1731301916Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.Vaccine2019https://conductscience.org/library/papers/31301916PubMed
1827002504Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.Vaccine2016https://conductscience.org/library/papers/27002504PubMed
1938242365Longitudinal study of meningococcal carriage in adolescents and young adults in South Australia 2017-2020.J Infect2024https://conductscience.org/library/papers/38242365PubMed
2033431159Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.Value Health2021https://conductscience.org/library/papers/33431159PubMed

See all 35 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42702664Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infect Dis Ther2026https://conductscience.org/library/papers/42702664PubMed
41790381Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States.Pharmacoeconomics2026https://conductscience.org/library/papers/41790381PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41345602

GET https://conductscience.org/api/papers/v1/41345602/references?page=2